Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Genome sequencing following Beta-d-N4-hydroxycytidine treatment of myeloid cell lines with variable expression of uridine-cytidine kinase 2

PROVIDER: PRJNA950474 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24029975_1.fastq.gz	Fastqsanger.gz
	SRR24029975_2.fastq.gz	Fastqsanger.gz
	SRR24029976.fastq.gz	Fastqsanger.gz
	SRR24029976_1.fastq.gz	Fastqsanger.gz
	SRR24029976_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 49

Similar Datasets

Project description:Assessment of uridine-cytidine kinase expression in cell lines and tissues from mice

| PRJNA1014119 | ENA

An Optimized Chemical-Genetic Method for Cell-Specific Metabolic Labeling of RNA

Project description:We demonstrate that mammalian cells are able to salvage uracil analogs, yielding high background incorporation into cellular RNA. We also discover the enzymatic pathways responsible for this background. To overcome these limitations, we have developed a novel small-molecule/enzyme pair consisting of uridine/cytidine kinase 2 (UCK2) and 2'-azidouridine (2'AzUd).

2020-04-01 | GSE136638 | GEO

Project description:Identification of genes that modify response to beta-d-N4-hydroxycytidine in mouse B cell lymphoma cell lines

| PRJNA950560 | ENA

Genetic and phenotypic changes to Venezuelan equine encephalitis virus following treatment with β-D-N4-hydroxycytidine, an RNA mutagen

Project description:Genetic and phenotypic changes to Venezuelan equine encephalitis virus following treatment with β-D-N4-hydroxycytidine, an RNA mutagen

| PRJNA853786 | ENA

β-D-N(4)-hydroxycytidine is a potent anti-alphavirus compound that induces high level of mutations in viral genome

Project description:The goal of this project was the analysis of virus variants resistant to β-D-N(4)-hydroxycytidine.

2017-11-13 | GSE106752 | GEO

Genetic and phenotypic changes to Venezuelan equine encephalitis virus following treatment with β-D-N4-hydroxycytidine, an RNA mutagen

Project description:The high mutation rate of RNA viruses provides viral populations with the ability to adapt to new environments but also makes them vulnerable to extinction due to the deleterious effects of mutations, which is the conceptual basis for the antiviral activity of RNA mutagens. However, there are still gaps in the quantitative understanding of the dynamics between the mutations induced by an RNA mutagen and its effects on viral fitness. To address this, we used Venezuelan Equine Encephalitis Virus (VEEV) and the potent RNA mutagen β-d-N4-hydroxycytidine (NHC) as a model to analyze virus replication competency and mutation frequency following treatment in the total and replication-competent viral populations separately. We found that NHC induced transition mutations in a concentration dependent manner in the total population, while the replication-competent population maintained itself within an increased, yet narrow, mutation spectrum. The incorporation of NHC mainly happened during the positive sense RNA synthesis of VEEV. A growth kinetic analysis of VEEV population treated with NHC pointed to a lower but more diverse distribution in mutational fitness, demonstrating that NHC-induced mutations negatively and broadly affect the fitness of the virus. Together, our study provides mechanistic insight into how RNA mutagens affect viral population landscape and the potential of RNA mutagens as an antiviral strategy for alphaviruses.

2024-10-25 | GSE207136 | GEO

Project description:Identification of Antibody-Resistant SARS-CoV-2 Mutants via N4-Hydroxycytidine Mutagenesis

| PRJNA1143956 | ENA

The active compound of Molnupiravir, N4-hydroxycytidine, promotes SARS-CoV-2 mutagenesis

Project description:The active compound of Molnupiravir, N4-hydroxycytidine, promotes SARS-CoV-2 mutagenesis

| PRJEB65430 | ENA

Project description:Germline mutagenicity of molnupiravir and its active form, beta-d-N4 hydroxycytidine, in Caenorhabitis elegans evaluated using shole genome sequencing

| PRJNA1256870 | ENA

Identification of beta-catenin-associated RNAs in myeloid leukaemia cells through RIP-seq

Project description:Myeloid cell lines (K562 and HEL) were treated overnight with CHIR99021 or a vehicle control (DMSO). CHIR99021 treatment inhibits GSK3B within the destruction complex functioning in Wnt/beta-catenin signalling pathway, thereby preventing beta-catenin degradation and promoting its stabilization. Following the overnight incubation, beta-catenin RIP (RNA immunoprecipitation) was performed in both K562 and HEL cells. RNA samples obtained from beta-catenin RIP in these cells were then sequenced to identify beta-catenin-associated RNAs under CHIR99021 treatment compared to basal conditions (DMSO control).

2025-04-08 | E-MTAB-14675 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data